Baystate Wealth Management LLC Has $2,966,000 Position in Johnson & Johnson (JNJ)
Baystate Wealth Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% during the third quarter, according to its most recent filing with the SEC. The fund owned 25,105 shares of the company’s stock after buying an additional 847 shares during the period. Johnson & Johnson makes up 0.6% of Baystate Wealth Management LLC’s portfolio, making the stock its 11th largest position. Baystate Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,966,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the stock. Avalon Advisors LLC raised its stake in shares of Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock worth $44,457,000 after buying an additional 101,250 shares in the last quarter. Fundsmith LLP raised its stake in shares of Johnson & Johnson by 24.1% in the second quarter. Fundsmith LLP now owns 3,704,693 shares of the company’s stock worth $449,379,000 after buying an additional 719,532 shares in the last quarter. Shelton Capital Management raised its stake in shares of Johnson & Johnson by 17.5% in the second quarter. Shelton Capital Management now owns 58,181 shares of the company’s stock worth $7,057,000 after buying an additional 8,669 shares in the last quarter. British Columbia Investment Management Corp raised its stake in shares of Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock worth $200,052,000 after buying an additional 17,000 shares in the last quarter. Finally, RKL Wealth Management LLC raised its stake in shares of Johnson & Johnson by 16.7% in the second quarter. RKL Wealth Management LLC now owns 43,943 shares of the company’s stock worth $5,167,000 after buying an additional 6,287 shares in the last quarter. 64.13% of the stock is currently owned by institutional investors and hedge funds.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.05% during trading on Wednesday, hitting $111.30. 11,178,468 shares of the stock were exchanged. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The stock’s 50 day moving average price is $115.58 and its 200-day moving average price is $118.34. The company has a market cap of $302.80 billion, a price-to-earnings ratio of 19.54 and a beta of 0.75.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm earned $17.80 billion during the quarter, compared to the consensus estimate of $17.71 billion. During the same period last year, the firm posted $1.49 EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $6.72 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, November 18th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.88%. Johnson & Johnson’s payout ratio is 56.64%.
Several equities research analysts have recently commented on the company. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research note on Monday, August 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target for the company in a research note on Friday, August 5th. BTIG Research reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. RBC Capital Markets set a $133.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Finally, Bank of America Corp. reiterated a “hold” rating and issued a $126.00 price target on shares of Johnson & Johnson in a research note on Monday. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $121.03.
In other news, Director Charles Prince purchased 875 shares of the stock in a transaction dated Friday, October 21st. The stock was acquired at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now directly owns 26,520 shares in the company, valued at approximately $3,026,197.20. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.